Comparison
Cagrilintide vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
1415456-99-3
no data
Molecular weight
4253.7 g/mol
888 g/mol
Half-life
168 h
no data
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYAc-LKKTETQMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
4
3
of which in humans
3
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
2